Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B)

Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B) is a phase 2, interventional study registered as NCT07795749 by University of California, Irvine, with a registry enrolment figure of 55 participants, started 2026-08-04 and due to reach its primary completion in 2029-08-31. Interventions recorded: Paclitaxel Q2W; Paclitaxcel Q3W. Conditions listed: Esophageal Carcinoma; Gastric Cancer (Diagnosis); Colorectal Adenocarcinoma; Appendiceal Adenocarcinoma; Small Bowel Adenocarcinoma; Hepatobiliary Carcinoma in Situ. Primary outcome: Protocol Treatment Completion Rate. Colorectal eligibility wording from the registry: "* Cohort B: Patients must have histologically or cytologically confirmed primary colorectal or appendiceal adenocarcinoma with PC". Sites: United States. No results are recorded here; the registry entry is the source.